Jefferies Financial Group Inc. Cuts Stock Position in Urogen Pharma (NASDAQ:URGN)

Key Points

• Jefferies Financial Group Inc. reduced its holdings in Urogen Pharma by 15.6%, owning 815,000 shares after selling 150,929 shares in the first quarter.
• Urogen Pharma reported a loss of ($0.92) EPS for the quarter, missing estimates, and had a negative net margin of 150.68% with revenue of $20.25 million.
• Analysts have set a consensus target price of $32.86 for Urogen Pharma, with several firms issuing "buy" ratings following recent updates.

Jefferies Financial Group Inc. decreased its position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) by 15.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 815,000 shares of the company's stock after selling 150,929 shares during the quarter. Jefferies Financial Group Inc. owned approximately 1.77% of Urogen Pharma worth $9,014,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. XTX Topco Ltd boosted its position in Urogen Pharma by 39.3% during the first quarter. XTX Topco Ltd now owns 25,967 shares of the company's stock valued at $287,000 after purchasing an additional 7,326 shares in the last quarter. ARK Investment Management LLC boosted its position in Urogen Pharma by 32.6% during the first quarter. ARK Investment Management LLC now owns 185,790 shares of the company's stock valued at $2,055,000 after purchasing an additional 45,642 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in Urogen Pharma by 14.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 786,472 shares of the company's stock valued at $8,698,000 after purchasing an additional 100,000 shares in the last quarter. CWM LLC boosted its position in Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Urogen Pharma by 701.8% during the first quarter. SG Americas Securities LLC now owns 162,514 shares of the company's stock valued at $1,797,000 after purchasing an additional 142,245 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

Wall Street Analyst Weigh In

URGN has been the subject of several recent analyst reports. Guggenheim reissued a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a report on Monday, July 7th. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Urogen Pharma has a consensus rating of "Buy" and an average target price of $32.86.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider directly owned 153,378 shares in the company, valued at approximately $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. This represents a 15.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,833 shares of company stock valued at $280,567. 4.70% of the stock is owned by company insiders.

Urogen Pharma Stock Up 0.2%

Shares of Urogen Pharma stock traded up $0.05 on Monday, reaching $19.45. 220,245 shares of the stock were exchanged, compared to its average volume of 1,588,527. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $19.74. The firm has a market capitalization of $898.45 million, a price-to-earnings ratio of -6.11 and a beta of 1.12. The business has a 50 day moving average price of $12.52 and a two-hundred day moving average price of $11.03.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.